PierianDx and Pillar Biosciences Announce Partnership to Support Precision Cancer Care
14.10.2020 15:00:00 EEST | Business Wire | Press release
PierianDx, the leading clinical genomics informatics company, and Pillar Biosciences, a leading next-generation sequencing clinical oncology company, today announced a partnership that enables Pillar Biosciences to sell directly the PierianDx clinical genomic report in combination with its cancer profiling assays. Under the agreement, PierianDx will integrate the Pillar Biosciences PiVAT® bioinformatics pipeline in the PierianDx environment to provide users with an accelerated implementation, including assay-specific variant filters, to produce best-in-class clinical genomics reports and enable a complete sample-to-answer solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201014005056/en/
Laboratories worldwide use Pillar Biosciences’ assays to detect pivotal genetic variants for cancer and other diseases. Pillar Biosciences’ targeted panels utilize a proprietary enrichment chemistry, SLIMamp®, that enables rapid, automated amplification of overlapping amplicons in a single tube using minimal sample inputs. Pillar Biosciences’ complementary bioinformatics pipeline, PiVAT®, is optimized for efficiency, reducing reflex testing and enabling low-frequency variant calling for every type of variant while consuming limited computing resources. PierianDx provides the Clinical Genomics Workspace™, which consists of intuitive software and a robust clinical Knowledgebase that transforms variant information into a highly-structured and comprehensive physician-ready report.
Streamlining NGS along with clinical genomic interpretation and reporting, especially for sophisticated panels, remains time-consuming and challenging. By packaging the Pillar Biosciences panels with the PierianDx report, the result will be an out-of-the-box clinical genomic report that is optimized for each assay. Furthermore, the solution will be available to customers globally through secure, and in the case of European regions, Global Data Protection Regulation (GDPR)-compliant, cloud instances. As a result, laboratories and healthcare organizations worldwide will have a highly reliable method for providing these tests to enable precision diagnostics and treatments for their patients.
“The assays from Pillar Biosciences provide robust detection for all variant types in a simplified workflow,” states Gang Song, PhD, CEO of Pillar Biosciences. “By optimizing variant filters and integrating with the PiVAT pipeline, PierianDx is streamlining interpretation and reporting, which adds substantial value for our customers.”
Rakesh Nagarajan, MD, PhD and Founder and Chief Technical and Visionary Officer of PierianDx, adds, “We are thrilled to provide this support for the Pillar Biosciences assays. As the market shifts to more sensitive assays in the LDT space and leading assay manufacturers seek in vitro diagnostic (IVD) approval, we are committed to addressing challenges that arise from even greater complexity in the interpretation and reporting process.”
About PierianDx
Founded in 2014 out of Washington University in St. Louis, PierianDx is focused on advancing cancer diagnostics and making targeted therapeutics more accessible to healthcare systems, laboratories, and patients worldwide. Its industry-leading clinical genomics technologies, CAP and CLIA accredited laboratory, IVD-ready knowledgebase and reporting solution, and expertise deliver the most integrated, trusted, and collaborative approach across the clinical care spectrum. From genomic sequencing and biomedical informatics in the laboratory to reporting and decision support at the patient’s bedside, PierianDx drives the adoption of genomics in clinical care and accelerates the fight against somatic cancer and hereditary germline diseases. www.pieriandx.com.
About Pillar Biosciences
Pillar Biosciences is a clinical cancer diagnostics company based in Boston, Massachusetts and Shanghai, China. Our automatable variant detection technologies deliver robust results with rapid turnaround times through streamlined NGS workflows. Our SLIMamp®– and PiVAT®-based products help high-throughput reference laboratories and clinical oncology laboratories make precision medicine practical by boosting their diagnostic productivity.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201014005056/en/
Contact information
Media contact for PierianDx:
Garreth Hippe
info@pieriandx.com
Media contact for Pillar Biosciences:
William Wright
info@pillar-biosciences.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom